For many patients with gastroesophageal reflux disease (GERD), proton pump inhibitors (PPIs) remain the treatment of choice, according to David Armstrong, MA, MB, BChir, FRCP (UK), FRCPC, FACG, AGAF, and colleagues. “However, despite PPI therapy, many patients with GERD continue to be symptomatic,” they write.
Trending
- Lessons from Sam Holliday, CEO and Co-Founder of Oshi Health, on Building a Virtual GI Center of Excellence (Pear Healthcare Playbook)
- UnitedHealth Adopts Aggressive Approach to Recover Ransomware Attack Loans (The HIPAA Journal)
- Cardinal Health’s acquisition of GI Alliance: What is means for the industry (Becker’s GI & Endoscopy)
- Why SIBO is often misdiagnosed as IBS [PODCAST] (KevinMD)
- Pfizer to discontinue its GLP-1 pill for obesity due to liver toxicity (STAT)
- The AI Paradigm: A Doctor’s Perspective (The Second Opinion)
- Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial (PRNewswire)
- Gas-sensing capsule takes another big step from lab to commercialization (EurekAlert!)